Clinical trials: Melanoma, Stage II
Melanoma
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer.
- Trial name
- NCT01740401
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Melanoma
Fecal Microbiota Transplant (FMT) in Melanoma Patients
The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
- Trial name
- NCT03341143
- Testing
- Fecal Microbiota Transplant with Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zarour, Hassane, MD
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT01585194
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and…
- Trial name
- NCT00071981
- Testing
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine
- Where
- 65 sites in United States
- Volunteers
- 175 people
- Sponsor
- Eastern Cooperative Oncology Group
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics
Melanoma (Skin)
0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
RATIONALE: Drugs used in chemotherapy, such as pentamidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00729807
- Testing
- pentamidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Melanoma
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib…
- Trial name
- NCT03625141
- Testing
- Cobimetinib, Atezolizumab, Vemurafenib
- Where
- 22 sites in Brazil, France and 6 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Melanoma, Metastatic Melanoma
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
This is a multicenter, open label, Phase 2 study, with 3 parallel cohorts. The aim of the study is to evaluate the efficacy of sotigalimab (APX005M) administered at 2 different schedules to adult participants with unresectable or…
- Conditions
- Unresectable Melanoma, Metastatic Melanoma, Cancer, Cancer of Skin
- Trial name
- NCT04337931
- Testing
- sotigalimab
- Where
- 19 sites in Poland, Spain
- Volunteers
- 45 people
- Sponsor
- Apexigen America, Inc.
Metastatic Melanoma, Skin Cancer
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Background: Some cancer treatments collect a patient s own blood cells to use as specialized cancer-fighting cells. Collected white blood cells known as PBL (peripheral blood lymphocytes) can use to isolate special cells that can…
- Trial name
- NCT01495572
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
The incidence of melanoma is increasing with an estimated incidence of 59,940 cases and an annual death rate of 8110 in 2007. Although patients diagnosed with early stage disease have an excellent clinical outcome, patients…
- Trial name
- NCT01079741
- Testing
- NY-ESO-1 protein; Poly-ICLC; Montanide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Nina Bhardwaj
Malignant Melanoma
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.
- Trial name
- UPCI-07-008 (NCT00715793)
- Testing
- Decitabine, Temozolomide, biopsy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Hussein Tawbi
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04527549
- Testing
- Dabrafenib mesylate, Hydroxychloroquine, Trametinib dimethyl sulfoxide
- Where
- 199 sites in United States
- Volunteers
- 5 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Recurrent Melanoma, Stage IIIc Melanoma
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
- Trial name
- NCT01316692
- Testing
- laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Melanoma (Skin)
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00404235
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 156 sites in United States
- Volunteers
- 76 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Trial of Pembrolizumab and Radiotherapy in Melanoma
Around 13,000 participants are diagnosed with melanoma in the UK each year and that number is growing quicker than any other cancer.
- Trial name
- PERM (NCT02562625)
- Testing
- Pembrolizumab, Radiotherapy
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Stage 0 Skin Melanoma, Stage I Skin Melanoma
Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
This clinical trial studies how well an interactive tailored website works in promoting sun protection and skin self-check behaviors in patients with stage 0-III melanoma.
- Conditions
- Stage 0 Skin Melanoma, Stage I Skin Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT03028948
- Testing
- Internet-Based Intervention, Questionnaire Administration, Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma (Skin)
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602576
- Testing
- sorafenib tosylate, temozolomide
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Abramson Cancer Center at Penn Medicine